Omapatrilat

Drug Profile

Omapatrilat

Alternative Names: BMS 186716; BMS 186716-01; Vanlev

Latest Information Update: 10 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihypertensives; Pyridines; Small molecules; Thiazepines
  • Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Angina pectoris; Heart failure; Hypertension; Myocardial infarction

Most Recent Events

  • 26 May 2003 Data presented at the 18th Annual meeting of the American Society of Hypertention (ASH-2003) have been added to the Hypertension pharmacodynamics section
  • 15 Oct 2002 The FDA have issued Bristol-Myers Squibb with an action letter regarding approval of Vanlev®
  • 24 Sep 2002 A study has been added to the adverse events and Heart Failure therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top